Use of low‐intensity extracorporeal shock wave therapy in the management of interstitial cystitis/bladder pain syndrome patients: A thirty case study in a tertiary medical center

Introduction Low‐energy extracorporeal shock wave therapy (LiESWT) is a new potential treatment for intractable interstitial cystitis/bladder pain syndrome (IC/BPS), and this paper will evaluate its therapeutic effects on IC/BPS. Materials and Methods This prospective clinical trial enrolled 30 wome...

Full description

Saved in:
Bibliographic Details
Published in:Neurourology and urodynamics 2023-01, Vol.42 (1), p.65-72
Main Authors: Jhang, Lan‐Sin, Hsieh, Wu‐Chiao, Huang, Ting‐Xuan, Chou, Yi‐Chun, Lo, Tsia‐Shu, Liang, Ching‐Chung, Lin, Yi‐Hao
Format: Article
Language:English
Subjects:
Cystitis
Cystitis, Interstitial - diagnosis
extracorporeal shock wave therapy
Extracorporeal Shockwave Therapy
Female
Humans
interstitial cystitis
Lithotripsy
Pain
Pain - drug therapy
Patients
Quality of Life
Questionnaires
Treatment Outcome
Urinary tract
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Low‐energy extracorporeal shock wave therapy (LiESWT) is a new potential treatment for intractable interstitial cystitis/bladder pain syndrome (IC/BPS), and this paper will evaluate its therapeutic effects on IC/BPS. Materials and Methods This prospective clinical trial enrolled 30 women who have been diagnosed with IC/PBS to receive LiESWT treatment at an intensity of 0.25 mJ/mm2 and a frequency of 3 pulses/second, for a total of 3000 pulses within 8 weeks. And we assessed questionnaires (including O'Leary‐Sant Interstitial Cystitis Symptom Index (ICSI)), 3‐day voiding diary, and urodynamic study at the following intervals: 4 weeks of LiESWT (W4), 8 weeks of LiESWT (W8), 1‐month follow‐up (F1), 3‐month follow‐up (F3) after LiESWT, and 1 year follow‐up (F12). Results The primary outcome of questionnaires showed significant improvement of symptoms compared to baseline (W0), especially on ICSI(12.87 ± 3.44 before treatment and 7.87 ± 5.27 at F12, p 
ISSN:0733-2467
1520-6777
DOI:10.1002/nau.25027